BioLife Solutions/$BLFS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioLife Solutions
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Ticker
$BLFS
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
159
ISIN
US09062W2044
Website
BLFS Metrics
BasicAdvanced
$1B
-
-$0.23
1.82
-
Price and volume
Market cap
$1B
Beta
1.82
52-week high
$29.55
52-week low
$18.70
Average daily volume
595K
Financial strength
Current ratio
4.73
Quick ratio
3.883
Long term debt to equity
4.159
Total debt to equity
4.195
Interest coverage (TTM)
-8.73%
Profitability
EBITDA (TTM)
0.368
Gross margin (TTM)
65.19%
Net profit margin (TTM)
-11.86%
Operating margin (TTM)
-5.76%
Effective tax rate (TTM)
0.47%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-0.79%
Return on equity (TTM)
-2.52%
Valuation
Price to revenue (TTM)
11.385
Price to book
2.9
Price to tangible book (TTM)
2.9
Price to free cash flow (TTM)
116.002
Free cash flow yield (TTM)
0.86%
Free cash flow per share (TTM)
18.53%
Growth
Revenue change (TTM)
34.80%
Earnings per share change (TTM)
-84.42%
3-year revenue growth (CAGR)
-14.11%
10-year revenue growth (CAGR)
31.62%
3-year earnings per share growth (CAGR)
-15.35%
10-year earnings per share growth (CAGR)
-2.94%
What the Analysts think about BLFS
Analyst ratings (Buy, Hold, Sell) for BioLife Solutions stock.
Bulls say / Bears say
KeyBanc Capital Markets increased BioLife Solutions' price target to $33, citing the company's transformation into a high-growth, high-margin entity under new leadership. (Investing.com)
Analysts project BioLife Solutions to achieve profitability by 2026, with an expected profit of $7.4 million, indicating a positive financial trajectory. (Yahoo Finance)
The company's Cell Processing platform, integral to marketed and developmental cell and gene products, demonstrates strong operational efficiency with a gross margin of 37.5% and revenue growth of 16.4% over the last twelve months. (Investing.com)
StockNews.com downgraded BioLife Solutions' stock rating to 'sell,' indicating potential concerns about the company's near-term performance. (MarketBeat)
Despite positive revenue growth, BioLife Solutions reported a net loss of $20.18 million over the last 12 months, reflecting ongoing profitability challenges. (TipRanks)
The company's high beta of 2.11 suggests greater volatility compared to the market, potentially leading to higher risk for investors. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BLFS Financial Performance
Revenues and expenses
BLFS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioLife Solutions stock?
BioLife Solutions (BLFS) has a market cap of $1B as of June 30, 2025.
What is the P/E ratio for BioLife Solutions stock?
The price to earnings (P/E) ratio for BioLife Solutions (BLFS) stock is 0 as of June 30, 2025.
Does BioLife Solutions stock pay dividends?
No, BioLife Solutions (BLFS) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next BioLife Solutions dividend payment date?
BioLife Solutions (BLFS) stock does not pay dividends to its shareholders.
What is the beta indicator for BioLife Solutions?
BioLife Solutions (BLFS) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.